Trials / Unknown
UnknownNCT05907408
Omics Techniques in Fatty Liver Disease
Precision Medicine in Fatty Liver Disease: How to Identify the Patient Who Develops Steatohepatitis Using Omics Techniques
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 10 (estimated)
- Sponsor
- Universidade Federal do Rio de Janeiro · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Nonalcoholic steatohepatitis (NASH) is the most common cause of chronic liver disease in Western countries and one of the leading causes of liver transplantation in the world. Its spectrum ranges from simple steatosis to decompensated cirrhosis, resulting from progressive fibrosis due to inflammation and cellular injury. The reasons why patients with the same degree of steatosis have different evolutions are not sufficiently known. The objective of this project is to identify biomarkers that predict disease progression, using omics techniques, which can serve to develop new therapeutic strategies.
Conditions
Timeline
- Start date
- 2023-07-01
- Primary completion
- 2023-10-01
- Completion
- 2023-12-31
- First posted
- 2023-06-18
- Last updated
- 2023-06-18
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT05907408. Inclusion in this directory is not an endorsement.